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Ames dwarf mice (df/df) have underdeveloped anterior 
pituitary glands due to a homozygous recessive deletion 
at the Prop1 locus. This loss of function mutation leads 
to primary hormonal deficiencies in growth hormone 
(GH), thyroid stimulating hormone (TSH), and prolactin 
(PRL) [1-3]. As a result, Ames dwarf mice have 
secondary deficiencies in insulin-like growth factor -
1(IGF-1) and thyroid hormones (T4). Furthermore, df/df 
mice have reduced circulating levels of insulin and 
glucose.  This   implies  enhanced  insulin  sensitivity,  a  
 
 









































conclusion which is supported by glucose tolerance and 
insulin tolerance tests, as well as by a recent study 
involving hyperinsulinemic-euglycemic clamps [4-7]. 
Importantly, Ames dwarf mice show a delayed aging 
process, demonstrated by enhancements in lifespan and 
healthspan including maintenance of higher insulin 
sensitivity and glucose tolerance throughout life, 
preservation of cognitive and neuromuscular function, 
and decreased occurrence of cancer [6, 8-12]. 
Mechanisms of the 40-60% increase in lifespan of df/df 
mice most likely include the interruption in 
somatotropic (GH/IGF-1) signaling and enhanced 




























effects of GH alone. Treatment of  female and male dwarfs with GH + T4 between  the ages of 2 and 8 weeks  rescued
somatic growth yet did not reduce lifespan to match normal controls, thus contrasting with the previously reported effects
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insulin sensitivity [5, 13, 14], along with enhancement 
of anti-oxidant defenses and stress resistance [15-20]. 
Numerous studies in several animal models reinforce 
the correlations between insulin sensitivity and the 
effects of GH on longevity. The dietary intervention of 
calorie restriction (CR) is a reduction in total calories 
consumed; it produces an increase in insulin sensitivity, 
lifespan, and healthspan in many animal species, 
including mice [4, 21-23].While both df/df mice and CR 
mice show positive signs of healthier aging, they appear 
to do so via different mechanisms, considering that 
df/df mice undergoing 30% CR exhibit a further 
extension of longevity [1, 4, 21, 24, 25]. Furthermore, 
Ames, Snell, and Laron dwarf mice all feature 
disruptions in the GH/IGF-1 axis and have reduced 
plasma concentrations of glucose and insulin, as well as 
increases in lifespan and healthspan when compared to 
normal littermates [8, 26].  
 
Insulin sensitivity is also related to aging and longevity 
in humans. Thus, glucose tolerance tends to decline 
with age and approximately 27% of the elderly over 65 
are being diagnosed with type 2 diabetes [27, 28]. In 
contrast, populations of centenarians have been shown 
to have improved insulin action, increased adiponectin, 
and either a reduction in serum IGF-1 levels or a higher 
prevalence of functional IGF-1 receptor mutations [29-
34]. There is a marked progressive decline in GH levels 
that begin after puberty [35, 36]. However, centenarians 
have not been shown to have significantly different 
levels of serum GH compared to normal, healthy aged 
individuals [37]. On the other hand, overexpression of 
GH is associated with detrimental effects on health in 
both humans and mice, including tumor development, 
insulin resistance, reduced antioxidant activity, reduced 
immune function, and shorter lifespan [38-41]. 
 
Treatment of juvenile male Ames dwarf mice with GH 
markedly increases somatic growth, but severely 
attenuates insulin sensitivity, glucose tolerance, cellular 
stress resistance, and longevity [5, 6, 42]. After GH 
treatment is discontinued, somatic growth slows down 
and body weight stabilizes at a level intermediate 
between normal (wild-type) and untreated Ames dwarf 
mice, while insulin sensitivity reduced by GH therapy is 
eventually restored [5]. The ability of early-life, six 
week GH treatment to reduce the longevity of Ames 
dwarf mice applies to both females and males and is 
reproducible (Hill, Arum and Bartke, unpublished 
observations). Juvenile male and female Ames dwarf 
mice treated for six weeks with thyroxine (T4) 
experienced increases in bodyweight, yet longevity was 
not significantly affected [6]. Young male Ames dwarf 
mice treated with a combination of GH and T4 
exhibited a major increase in bodyweight, approaching 
the body weight of their normal siblings. The treatment 
with GH plus T4 also led to increased plasma insulin, 
decreased adiponectin, and decreased expression of 
insulin signaling components in the liver [43]. 
 
In the present study, we have examined the impact of 
six weeks of treatment of juvenile Ames dwarf mice 
with a combination of GH and T4 on their longevity. 
We also analyzed the effects of treating female Ames 
dwarf mice with GH alone or with GH plus T4 on the 
expression of genes involved in insulin signaling in 
skeletal muscle (SM) and white adipose tissue (WAT). 
To determine the effects of the hormonal intervention 
we performed an analysis of the expression of genes 
involved in the insulin signaling pathway, including 
insulin receptor (IR), insulin receptor substrate-1 (IRS-
1), and phosphatidylinositol bisphosphate 3-kinase 
(PI3K). Next, we investigated an important fulcrum in 
insulin signaling pathway, the serine/threonine kinase 
Akt2, as well as genes of its downstream effectors, 
namely GLUT4 and forkhead box O3 (FOXO3). The 
mRNA levels of the transcription factor peroxisome 
proliferator-activated receptor gamma (PPAR-γ), 
peroxisome proliferator-activated receptor gamma 
coactivator 1 alpha (PGC-1α), and Adiponectin (an 
adipokine) were examined, as they are important 
modulators of insulin sensitivity, glucose utilization, 
and lipid metabolism. Additionally, to determine the 
activation of GH signals in df/df mice after the 
treatment, we examined the expression of the growth 
hormone receptor (GHR) gene and genes related to its 
downstream effects, including insulin-like growth 






Consistent with our previous reports [4, 6, 18], Ames 
dwarf mice lived significantly longer than normal 
animals (p < 0.0001; log-rank test). Average longevity 
of female and male Ames dwarf mice that had been 
treated with GH + T4 between 2 and 8 weeks of age did 
not differ from the longevity of dwarf mice of the same 
sex that had been injected with saline. We used the 
Wang/Allison method to compare the proportion of live 
mice in each group at the age at which only 10% of the 
population remained alive [44]. Maximal longevity of 
female (p = 0.0128 by Fisher's exact test), but not male 
Ames dwarf mice, was reduced by GH + T4 treatment. 
Unexpectedly, treatment of normal juvenile male (but 
not female) mice with GH + T4 for 6 weeks produced a 
small but statistically (p = 0.0360; log-rank test) 
significant increase in overall longevity (Figure 1). 
  
























Body weight and Glucose Level 
 
At the age of 2 months, body weight of the Ames dwarf 
mice was significantly lower than phenotypically 
normal (N) control mice as expected (p < 0.0001). 
However, after six weeks of treatment with GH or GH 
and T4, the df/df mice were significantly larger than 
saline treated mutants (p < 0.0001) and matched the 















































Female df/df-GH mice showed a numerical increase of 
fasting blood glucose levels reaching values higher 
than the levels measured in the normal mice (p < 
0.05). However, dwarf mice treated with GH and T4 
showed no such increase with fasting blood glucose 




























(df/df) mice with  either  no  treatment  (saline)  or  treated with  a  combination  of  growth  hormone  and
thyroxine (GH + T4) (n = 24 animals per group). 
 




that  do  not  share  a  superscript  are  different with  statistical
significance (p < 0.05). 
 




that  do  not  share  a  superscript  are  different with  statistical 
significance (p < 0.05). 
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Gene Expression: Skeletal Muscle 
 
There were no differences in insulin receptor (IR) gene 
expression in the skeletal muscle tissue between N, 
df/df and df/df-GH mice, while df/df-GH + T4 mice had 
reduced IR mRNA expression (p < 0.01). IRS-1 gene 
expression was significantly increased in df/df-GH mice 
when compared with df/df animals (p < 0.01), yet in the 
group given GH plus T4, this effect of GH was 













































Ames dwarfism or treatment with GH alone. However, 
combined treatment with GH + T4 significantly reduced 
PI3K mRNA expression in comparison to both N mice 
and mice treated with GH alone (p < 0.01) (Figure 4). 
The expression level of skeletal muscle Akt2 was 
decreased in df/df mice when compared to N mice (p < 
0.05). GH treatment normalized the expression of Akt2, 
while GH-T4 treatment did not with no significant 
difference from values measured in untreated df/df mice 









































































































The level of PPAR-γ mRNA in skeletal muscle was not 
altered in df/df mice and not affected by GH therapy. 
However, combined GH-T4 treatment significantly 




















































(Figure 5). The expression level of PGC-1α was 
decreased in all groups of Ames dwarf mice, regardless 
of the treatment (p < 0.05). The growth hormone 
receptor (GHR) mRNA level was not altered in GH-
Figure  5.  (A) Peroxisome Proliferator‐Activated Receptor (PPAR) γ, (B) PPAR Coactivator 1α (PGC‐1α),
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deficient df/df mice and was not affected by GH. 
Interestingly, df/df-GH + T4 mice showed a decrease in 
the expression level of GHR when compared with either 
N (p< 0.005), df/df (p < 0.05), or df/df-GH animals (p < 
0.05) (Figure 5). The IGF-1 mRNA level in the skeletal 
muscle was significantly increased in df/df mice when 
compared to N animals (p < 0.005), and GH treatment 
caused a further increase of local IGF-1 expression 
(when compared with either N or df/df mice; p < 0.0005 
and p < 0.005, respectively). Interestingly, addition of 












































ed the expression of IGF-1 mRNA in df/df-GH + T4 at 
the level observed in df/df control mice (Figure 5). In 
comparison to N animals, control Ames dwarf mice had 
markedly reduced GLUT4 gene expression in (p < 
0.005), and treating them with GH alone increased 
GLUT4 gene expression to the levels found in normal 
mice (p < 0.01). In contrast, treatment with GH plus T4 
suppressed GLUT4 gene expression to levels below 
those measured in the df/df and df/df-GH groups (p < 




























































































Growth hormone treatment of dwarf mice elevated 
STAT-1 gene expression (p < 0.05), but combined GH 
and T4 therapy did not. STAT-1 expression in animals 
treated with GH + T4 mice was significantly lower than 
in the group given GH alone (p < 0.005). The STAT-5a 
expression was not affected by genotype or by either of 
the treatments (Figure 6). However, STAT-5b 
expression was reduced by GH treatment of df/df mice 
(p < 0.05), and GH-T4 treatment led to a further 
significant decrease in the expression of this gene (p < 
0.01). The expression of FOXO3 transcription factor 
was decreased in df/df-GH + T4 group in comparison to 
N, df/df and df/df-GH animals (P < 0.005, p < 0.05, and 










































ponectin mRNA levels in untreated df/df mice (p < 
0.05), were normalized by GH treatment (p < 0.05) but 
were not affected by administration of GH together with 
T4 (Figure 6).  
 
Gene Expression: White Adipose Tissue 
 
The level of IR mRNA in white adipose tissue (WAT) 
did not differ between N and df/df mice. Growth 
hormone treatment suppressed IR mRNA expression in 
dwarf mice (p < 0.001) with further significant decrease 
in animals given GH + T4 (p < 0.005). Interestingly, IR 
expression in df/df-GH + T4 animals was significantly 
lower  than  in  N  mice  (p < 0.05).  The  IRS-1  mRNA  
Figure  7. (A) Insulin Receptor (IR), (B) Insulin Receptor Substrate‐1 (IRS‐1), (C) Phosphoinositide 3‐Kinase (PI3K),
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expression level was increased in df/df mice when 
compared with N animals (p < 0.005), and normalized 
by treatment with GH and T4 (p < 0.005), but not with 
GH alone (Figure 7). PI3K mRNA expression was 
elevated in df/df mice when compared to N littermates 
(p < 0.05). GH treatment normalized PI3K expression 
(p < 0.05), while GH plus T4 treatment led to a further 















































pared with N, df/df and df/df-GH groups, p < 0.005, p < 
0.005, p < 0.05, respectively). The level of Akt2 mRNA 
was up-regulated in df/df when compared to N mice (p 
< 0.05), not affected by treatment with GH alone but 
reduced by treatment with GH + T4 to levels 
significantly below those measured in the df/df an df/df-
GH groups (p < 0.005 and p < 0.01, respectively) 







































































































Both GH and GH + T4 treatment decreased PPAR-γ 
gene expression level in WAT of df/df mice (compared 
with df/df mice, p <0.05, p< 0.005 respectively). 
Moreover, animals in the df/df-GH + T4group had 
lower PPAR-γ expression than the df/df-GH group (p < 
0.05) (Figure 8), PGC-1α mRNA levels were 
significantly increased in the WAT of Ames dwarf mice 
















































GH + T4 treatment suppressed PGC-1α mRNA in df/df-
GH and df/df-GH + T4 mice to the levels maintained by 
N mice (p < 0.0001, p < 0.0005 respectively). The level 
of GHR mRNA was not altered in untreated df/df mice 
and treatment with GH increased it to a level higher 
than in N animals (p < 0.01). Interestingly, the 
combined GH plusT4 therapy caused a decrease inGHR 
gene expression, when compared with N, df/df, and 
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df/df-GH mice (p < 0.05, p < 0.05and p < 0.005, 
respectively).The expression of IGF-1 in the adipose 
tissue of Ames dwarf was reduced (p < 0.005). GH 
treatment increased IGF-1 mRNA levels in comparison 
with N and df/df littermates (p < 0.0005 and p < 0.0001, 
respectively); while, combined treatment with GH and 
T4 had a much smaller effect leading to normalization 
of IGF-1 expression. Ames dwarf controls showed 
increased expression of the GLUT4 gene vs. N mice (p 
< 0.01). While GH treatment had no significant effect 
on the expression of this gene, treatment with GH plus 
T4 significantly decreased GLUT4 mRNA levels when 
compared with df/df and df/df-GH mice (p < 0.001 and 
p < 0.005, respectively), normalizing it to the level 
observed in N animals (Figure 8). 
 
STAT-1 and STAT-5a gene expression were increased 
in df/df as compared to N mice (p < 0.01) and 
normalized by the treatment with either GH or GH + T4 
(both p < 0.05) (Figure 9),. The expression of STAT-5b 
showed upregulation in df/df mice when compared with 
N animals and decreases in response to both GH (p < 
0.05) and combined GH + T4 therapy (p < 0.0005). The 
level of STAT-5b mRNA in df/df-GH + T4 mice was 
lower than in df/df-GH and N mice (p < 0.01 and p < 
0.005, respectively). Similarly to the findings with 
STAT-5b, the expression of FOXO3 was elevated in 
df/df mice in comparison to N animals (p < 0.05), and 
significantly decreased by treatment with GH or GH + 
T4 in comparison to saline-injected df/df mice (p < 
0.05, p < 0.0001). Adiponectin expression levels did not 
differ between N, df/df, and df/df-GH animals. 
However, df/df-GH + T4 mice had decreased WAT 
levels of adiponectin mRNA when compared with N, 
df/df, and df/df-GH counterparts (p< 0.01, p < 0.005, p 




Treatment of juvenile Ames dwarf mice with a 
combination of GH and T4 for a period of 6 weeks did 
not affect their average longevity. Reduction of 
maximal longevity was detected only in females. These 
findings contrast with the ability of treatment with GH 
alone during the same period of development to reduce 
longevity in both female and male dwarfs from the 
same breeding colony ([6]; Hill Arum & Bartke, 
unpublished observations). This difference between the 
effects of treating juvenile Ames dwarf mice with GH + 
T4 vs. GH -only treatment was unexpected, particularly 
because both treatments produced a major increase in 
somatic growth. However, six weeks of treatment of 
juvenile Ames dwarfs with T4 alone did not impact 
longevity in our previous study [6], even though 
somatic growth was modestly increased. We have no 
explanation for a small but statistically significant 
increase in longevity in normal males treated with GH + 
T4 between the ages of 2 and 8 weeks or for the absence 
of a similar effect in females. Interpretation of findings 
in normal animals is complicated by the impact of 
injected GH and T4 on the functions of the 
somatotropic and the hypothalamic-pituitary-thyroid 
axis, which was not examined in the present study. 
 
In an attempt to identify mechanisms that could have 
been responsible for the differential impact of the 
treatment with GH + T4 vs. GH alone on longevity, we 
have examined expression of a number of genes related 
to GH, IGF-1 and insulin signaling in the skeletal 
muscle and WAT, important target tissues for these 
hormones. The animals received GH or GH + T4 using 
treatment protocols identical to those employed in the 
longevity studies ([6, 43] and the present study) but 
were euthanized on the day following the last injection 
to compare the molecular alterations involved by these 
hormonal regimens. 
 
There was no difference in bodyweight between GH 
and GH + T4 treated Ames dwarf mice at the time of 
sacrifice and the average body weights of df/df-GH and 
df/df-GH + T4 mice matched the values in the N control 
group. This differs from the results obtained by Louis et 
al. [43], who reported that treatment of male Ames 
dwarf mice with the same doses of GH as employed in 
the present study did not fully normalize their body 
weight. This difference may be related to the fact that 
during the pre- and peripubertal period, male mice grow 
more rapidly than females and reach higher body weight 
at the age of 8 weeks (approximately 25 vs. 19 g). Our 
failure to detect a reduction in blood glucose levels in 
dwarf as compared to normal mice represents another 
difference from the results of previous studies [5, 6, 45]. 
The present lack of difference in blood glucose level 
can be potentially explained by the very young age of 
the animals. Both df/df and N mice were at the age of 8 
weeks and, at this age, N mice show no signs of insulin 
resistance. In our previous work, we have shown that 
the major differences in insulin resistance begin to 
appear when the mice are approximately 15 months old, 
which is most likely due to a decrease of insulin 
sensitivity during aging in N mice and better 
maintenance in long-living mutants [46].  
 
Dominici and colleagues have shown that the alterations 
in insulin sensitivity in df/df mice can be tissue specific 
[47], which is consistent with our recent euglycemic-
clamp study of Ames dwarf mice [7]. In the present 
study IR, IRS-1, and PI3K gene expression in skeletal 
muscle showed no difference between dwarf and 
normal female mice. In WAT, IRS-1, PI3K, and Akt2 
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expression did differ between the N and df/df control 
groups and these differences were eliminated by 
treatment of the dwarfs with GH.  
 
Combined treatment with GH + T4 suppressed IR 
expression in both WAT and muscle, and decreased 
IRS-1 expression to the levels measured in normal 
controls. Compared to the normal controls, IGF-1 
mRNA levels in Ames dwarf mice were increased in 
SM and reduced in WAT, however, the observed 
reduction was not as severe as previously observed in 
hepatic tissue or in plasma. This different regulation of 
IGF-1 in examined tissues, especially in SM, represents 
GH-independent local regulation of IGF-1 in these 
tissues. It was previously reported that df/df mice have 
normal levels of IGF-1 protein and mRNA in the 
hippocampus when compared to N animals [48]. This 
and other data suggest that GH mainly regulates hepatic 
IGF-1 and its secretion to the circulation. However, 
other organs can produce this growth factor, but make 
only minor contributions to the circulating levels of 
IGF-1 [49-52]. GH-only treatment drastically increased 
local IGF-1 mRNA in both tissues while including T4 
in the treatment regimen negated the effects of therapy 
with GH alone. Thus, female dwarf mice readily 
respond to treatment with GH and T4 in terms of 
somatic growth, but fail to exhibit major changes in the 
expression of genes related to insulin signaling in the 
skeletal muscle or in WAT in response to this treatment. 
Moreover, the results indicate that concurrent use of 
exogenous T4 can modify the effects of GH therapy on 
expression of numerous genes. 
 
Reviewing the gene expression results, a common trend 
between both tissues examined in the present study is 
apparent. In the muscle, the mRNA levels for the genes: 
IR, PI3K, Akt2, GHR, IGF-1, GLUT4, STAT-1, STAT-
5b, and FOXO3, were lower in animals treated with GH 
+ T4 than in those treated with GH alone. In WAT, the 
combined treatment decreased IR, IRS-1, PI3K, Akt2, 
PPAR-γ, GHR, IGF-1, GLUT4, STAT-5b, FOXO3, and 
adiponectin gene expression. In both SM and WAT, GH 
treatment alone failed to alter PPAR-γ gene expression, 
yet GH + T4 treatment led to PPAR-γ mRNA decreases 
in both tissues. However, some major differences were 
also apparent. For PGC-1α, both treatments produced 
expression levels mimicking those in the N control 
group in the WAT but not in the muscle. GLUT4 
showed strikingly different effects of genotype and 
treatment in SM as compared to WAT. 
 
Differential impact of GH + T4 treatment on longevity 
of males and females was not entirely unexpected. 
There are major sex differences in the pulsatile pattern 
of GH secretion in both humans and rodents [53-55]. 
Females have a higher baseline level of GH, as well as 
larger and more prolonged GH secretory periods 
compared to males. In males, GH is present at lower 
basal levels but maximal GH plasma concentrations are 
higher. Thus, the twice daily GH treatment regimen 
used in the present study may have more closely 
mimicked the natural GH secretion patterns of males, 
reaching higher plasma peak concentrations for a 
shorter duration [53, 56, 57]. In this study, it is apparent 
that there are some sex-related differences in the effects 
of this hormonal therapy, as seen by the different effects 
on lifespan. Interpreting the changes in gene expression, 
it must be mentioned that changes in the mRNA levels 
do not always correlate to changes in translation and 
protein expression. Additional, more extensive studies 
would be needed to evaluate the levels and 
activation/deactivation of different signaling proteins to 
determine what steps of the pathway are being regulated 
by these hormones in the different tissues. These 
additional steps are necessary as we reported that df/df 
mice have higher whole body insulin sensitivity with 
corresponding enhanced glucose uptake by WAT and 
SM [7]. However, the present results based on our 
measurements of mRNA levels indicate that the 
regulation of this signal may differ in these two major 
insulin dependent organs. These differences may have 
been related to the timing of tissue collection or to 
compensatory adjustments in the insulin signaling 
pathway in experiments involving acute stimulation by 
insulin. 
 
 Furthermore, it would be pertinent to analyze the 
effects of hormonal treatment on these molecular 
signaling pathways at different stages of life and at 
different times after completion of the hormonal 
therapy. These future longitudinal experiments would 
allow the detection of persistent or permanent changes 
that GH or GH + T4 may induce during development. 
This could identify genes or pathways that could affect 
our lifespan or healthspan via developmental 
programming. 
 
In conclusion, combining T4 treatment with GH therapy 
suppressed mRNA expression for several genes 
including GLUT4 and IGF-1compared to GH injections 
alone. Thyroxine suppressed the expression of genes 
involved in the GH signaling pathway in the muscle, 
including the GHR gene, thus counteracting some of the 
effects of GH replacement in the GH + T4 group. It is 
tempting to speculate that these actions of exogenous 
T4 may have been responsible for eliminating the 
impact of concomitant GH therapy on longevity, or at 
least may have contributed to the differential impact of 
GH + T4 vs. GH alone on lifespan. It is also possible 
that the impact of thyroid hormones on the development 
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and maturation of the central nervous system and other 
organs results in shortening or a temporal shift of the 
period when GH can produce effects (most likely 
epigenetic) that alter the course of aging and modulate 
longevity. By elucidating the effects of GH and T4 
replacement therapy on the insulin signaling pathway of 
GH and TSH deficient Ames dwarf mice, we hope to 
enhance understanding of the interactions between these 
hormones in the physiological control of whole body 
insulin sensitivity, aging and longevity. Progress in this 
area could support development of new, safe ways to 
improve glucose homeostasis in type 2 diabetic patients 
and in the elderly, promoting better health and quality 
of life for the future. 
 
MATERIALS AND METHODS 
 
Animals. In a breeding colony, phenotypically normal 
heterozygous (N) females were mated with homozygous 
dwarf (df/df) mutant males to produce the Ames dwarf 
and N mice. The mice were housed under light- and 
temperature- controlled conditions, with a 12-hour light 
and 12-hour dark cycle and the temperature maintained 
at 20-23⁰C. Nutritionally balanced food was provided 
ad libitum (Rodent Laboratory Chow 5001: 23.4% 
protein, 4.5% fat, 5.8% crude fiber; LabDiet PMI Feeds, 
Inc., St Louis, MO). The animal studies were completed 
at Southern Illinois University in Springfield Illinois 
following SIU Laboratory Animal Care Committee 
approval [42, 43]. 
 
Effects of treatment of juvenile normal and ames dwarf 
mice with GH plus T4 on longevity. Exogenous T4 
stimulates somatic growth of Ames dwarf mice and 
enhances the growth-promoting effects of GH [6, 43]. 
Treatment of juvenile Ames dwarfs with GH reduces 
their longevity, while treatment with T4 does not [6]. In 
view of these observations, we decided to examine the 
impact of early-life treatment with a combination of GH 
and T4 on the longevity of normal and Ames dwarf 
mice. Starting at the age of 2 weeks, female and male 
normal and Ames dwarf mice were injected twice daily 
with saline or with porcine GH (twice daily) plus L-
thyroxine (three times per week) (See details later in 
section). The treatments were continued for six weeks. 
There were 24 animals per genotype/sex/treatment 
group (i.e. 24 N male control mice, 24 N male GH + T4, 
24 df/df male control, 24 df/df male GH + T4, 24 N 
female control mice, 24 N female GH + T4, 24 df/df 
female control and 24 df/df female GH + T4). The 
animals were checked daily for survival. The dates of 
death were recorded. In some instances, animals that 
appeared moribund and unlikely to survive longer than 
another 24-48 hours were euthanized and the date of 
euthanasia was used for longevity determination. 
Comparison of the effects of treatment with GH alone 
vs. GH plus T4. At the age of 2 weeks, phenotypically 
normal and Ames dwarf female mice were divided into 
four experimental groups, including: (i) a control group 
of normal heterozygous (N) mice injected with 0.9% 
saline, (ii) Ames dwarfs (df/df) treated with 0.9% 
saline, (iii) Ames dwarfs treated with porcine GH 
(df/df-GH), and Ames dwarfs treated with GH and T4 
(df/df-GH + T4). There were 8-10 animals in each 
group. Hormone treatment started at 2 weeks of age and 
continued for 6 weeks. Twenty-four hours after the last 
injection and after an overnight fast, the mice were 
sacrificed by isoflurane anesthesia followed by cervical 
dislocation. Fasting blood glucose levels were measured 
before sacrifice in blood collected from the tail vein 
using the OneTouch Ultra glucose meter (Life Scan, 
Inc. Milpitas, CA). Tissues were harvested, immediately 
frozen on dry ice and stored at -80⁰C until analysis [42, 
43]. 
 
Treatment. For preparation of the GH, porcine GH 
(Alpharma, Victoria, Australia) was dissolved in 0.1M 
NaHCO3 for stability, then 0.9% saline was added to 
make a single injection concentration of 21μg/50μL for 
the average animal body weight of 7g (3μg/g of body 
weight); pH was adjusted from 8.3 to 7.8. GH injections 
were performed twice a day on weekdays with each 
subcutaneous injection administering half the daily dose 
(~3μg/g); the first injection was ~9am and the second 
was ~4pm (~6μg/g/day total GH treatment). On 
weekends, only one injection was performed with the 
full daily dosage (~6μg/g/day).  
 
For the preparation of the T4, L-thyroxine (Sigma, St 
Louis, MO) was dissolved in a 0.9% saline solution 
with a pH of 7.8. It was administered three times per 
week (Monday, Wednesday, and Friday) via 
subcutaneous injections (0.1μg/g body weight; 0.7 
μg/50μL dose) and administered in conjunction with the 
respective morning GH doses, albeit delivered in 
separate injections. 
 
The doses were selected on the basis of previous studies 
in Ames dwarf mice [42, 43]. 
 
Real-time PCR. Hind leg skeletal muscle and peri-
ovarian white adipose tissue (WAT) RNA were used for 
the analysis of the expression levels of the following 
genes: IR, IRS-1, PI3K, Akt2, PPAR-γ, PGC-1α, GHR, 
IGF-1, GLUT4, STAT-1, STAT-5a, STAT-5b, 
Adiponectin, and FOXO3. First, total mRNA was 
extracted from the sample tissue using the Qiagen 
miRNeasy Mini Kit. Approximately 75mg of skeletal 
muscle tissue was cut from each sample, and then 
placed in a 1.5mL safe-lock tube with 1mm Zirconium 
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oxide beads and 700μL of QIAzol Lysis Reagent. 
Samples were homogenized in a bullet blender at speed 
10 for 2 minute periods, and then cooled on wet ice for 
2 minutes. This process of blending and cooling was 
repeated 3 times per sample, or until well homogenized. 
From here, the Quick-start Protocol included in the kit 
was followed as outlined by Qiagen, including the 
DNase digest steps. The result of using the kit was 
approximately 40μL of purified mRNA in nuclease free 
water (NF H2O). Approximate total RNA concentration 
was determined for normalization using agarose gel 
electrophoresis as well as Nanodrop procedure with the 
Epoch Gen5 Plate Reader (see appendix for procedure 
details). RNA extraction from white adipose tissue was 
performed in the same way, except 50-60mg of sample 
tissue was used, 0.5mm Zinc Oxide beads were used, 
and the bullet blender was set at speed 8 for 3 min. 
 
Following the RNA extraction procedure, the cDNA 
synthesis was performed using the Bio-Rad iScript kit. 
After combining the master-mix (5x iScript reaction 
mix and iScript reverse transcriptase) with mRNA 
templates (derived from the tissue samples) in PCR 
tubes according to protocol, the reaction mix samples 
were placed into a Bio-Rad MJ Mini Personal Thermal 
Cycler. The machine conditions were set at 25⁰C for 5 
min, 42⁰C for 30 min, and 85⁰C for 5 min, and then 
held at 4⁰C when finished. This led to cDNA samples in 
20μL of NF H2O; NF H2O was added to each sample to 
dilute them and narrow the range of B2M cycle 
threshold (CT) values with RT-PCR (see below). The 
cDNA samples were stored at 4⁰C until analysis (if 
there was a longer period of time between cDNA 
synthesis and RT-PCR analysis, the cDNA samples 
were frozen at -20⁰C). 
 
This cDNA was used for RT-PCR analysis. 2μL of 
cDNA was used per sample in a 96 well PCR plate. The 
forward and reverse primers for the gene of interest 
were prepared with SYBR Green and NF H2O in a 
master mix according to Applied Biosystems protocol, 
then added to the 96 well plate containing the cDNA 
samples for a total of 20μL per well. For PCR protocol 
and table of primers used, see appendix. 
 
To normalize the RT-PCR data, beta 2-Microglobulin 
(B2M) was selected as the housekeeping gene. When 
CT values had a maximum range of 3 between all 
samples, gene analysis began. The following equation 
was used for calculating relative expression: 2A-B/2C-D 
(A = CT value of the gene of interest in the first 
control sample, B = CT value of the gene of interest in 
each sample, C = CT value of B2M in the first control 
sample, D = CT value of B2M in each sample). This 
led to the first control sample having a relative 
expression of 1, and all other samples were calculated 
in relation to this first sample. The results of the 
normal (N) group were averaged, and all other results 
were divided by this average to obtain the fold change 
of expression of the genes of interest compared to this 
control group [43]. 
 
Statistical analysis – longevity. Overall survival was 
tested by log-rank test, using GraphPad Prism 5.  
Maximal survivorship was evaluated as previously 
described [44]. 
 
Statistical analysis – RT PCR. Microsoft Excel and 
GraphPad Prism5 software was used to calculate the 
raw data. Statistics were calculated on Prism5 via one-
tailed P-values for unpaired t tests. Differences between 
groups that generated a p-value less than 0.05 were 
considered statistically significant.                                                    
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